

## Supplementary

### **Efficacy and Safety of Bimekizumab in Japanese Patients with Generalised Pustular Psoriasis and Erythrodermic Psoriasis: 3-Year Results from BE BRIGHT, a Multicentre, Open-Label, Phase 3 Study**

Yukari Okubo,<sup>1</sup> Yayoi Tada,<sup>2</sup> Hidetoshi Takahashi,<sup>3</sup> Masatoshi Abe,<sup>4</sup> Keiichi Yamanaka,<sup>5</sup> Nicola Tilt,<sup>6</sup> Nancy Cross,<sup>7</sup> Delphine Deherder,<sup>8</sup> Mizuho Matano,<sup>9</sup> Hidemi Nakagawa<sup>10</sup>

*<sup>1</sup>Department of Dermatology, Tokyo Medical University, Tokyo, Japan;*

*<sup>2</sup>Department of Dermatology, Teikyo University School of Medicine, Tokyo, Japan; <sup>3</sup>Takagi Dermatological Clinic, Obihiro, Japan; <sup>4</sup>Sapporo Skin Clinic, Sapporo, Japan; <sup>5</sup>Department of Dermatology, Mie University Graduate School of Medicine, Tsu, Japan; <sup>6</sup>UCB, Slough, UK; <sup>7</sup>UCB, Morrisville, North Carolina, USA; <sup>8</sup>UCB, Braine-l'Alleud, Belgium; <sup>9</sup>UCB, Tokyo, Japan; <sup>10</sup>The Jikei University School of Medicine, Tokyo, Japan*

Corresponding author: Prof. Yukari Okubo, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo 160-0023, telephone: 03-5339-3136, fax: 03-3342-3535, [yukari-o@tokyo-med.ac.jp](mailto:yukari-o@tokyo-med.ac.jp)

**Table S1. Key inclusion and exclusion criteria**

|                           | <b>GPP</b>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             | <b>EP</b>                                                                                                                                                                                |
|---------------------------|----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------|
| <b>Inclusion criteria</b> | <ul style="list-style-type: none"> <li>• Male or female aged <math>\geq 18</math> years</li> <li>• Candidate for systemic psoriasis therapy and/or phototherapy</li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                                             |                                                                                                                                                                                          |
|                           | <ul style="list-style-type: none"> <li>• Diagnosis of GPP at screening, based on JDA diagnostic criteria</li> <li>• Total score on the JDA severity index <math>&lt;14</math></li> </ul>                                                                                                                                                                                                                                                                                                                                                                                                                                                                                               | <ul style="list-style-type: none"> <li>• Diagnosis of EP at screening</li> <li>• History of plaque-type psoriasis</li> <li>• BSA affected by psoriasis <math>\geq 80\%</math></li> </ul> |
| <b>Exclusion criteria</b> | <ul style="list-style-type: none"> <li>• Previously participated in another study with BKZ or another investigational medication</li> <li>• Are female with plans to become pregnant during the study or within 20 weeks after last dose of BKZ</li> <li>• Has any medical or psychiatric condition that could compromise ability to participate in this study</li> <li>• Has guttate psoriasis or drug-induced psoriasis</li> <li>• Differential diagnosis of erythroderma other than EP (i.e., erythroderma cause by lymphoma or drug eruption)</li> <li>• Had a primary failure to any prior biologic therapy (i.e., no response within the first 12 weeks of treatment)</li> </ul> |                                                                                                                                                                                          |

While patients with PSO were required to have IGA  $\geq 3$  for inclusion in the study, patients with GPP or EP were not required to have an IGA  $\geq 3$  for inclusion. BKZ: bimekizumab; BSA: body surface area; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; JDA: Japanese Dermatological Association; PSO: plaque psoriasis.

**Table S2. Dose of concomitant systemic medications related to GPP and EP over 144 weeks: (a) Weeks 1–52, (b) Weeks 56–112, and (c) Weeks 116–144.**

**(a) Weeks 1–52**

|                               | Week                    |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
|-------------------------------|-------------------------|-------------------------|-------------|-------------|-----------|-----------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                               | 1                       | 2                       | 4           | 8           | 12        | 16        | 20                   | 24                   | 28                   | 32                   | 36                   | 40                   | 44                   | 48                   | 52                   |
| <b>GPP (N=10)</b>             |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-1</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-2</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-3</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | 100 mg Qam,<br>50 mg Qn | 100 mg Qam,<br>50 mg Qn | 50 mg twice | 50 mg twice | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-4</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Etretinate                    | 20 mg QD                | 20 mg QD                | 20 mg QD    | 20 mg QD    | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>BKZ 320 mg Q4W/Q8W/Q4W</b> |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-5</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-6</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Prednisolone                  | 10 mg QD                | 10 mg QD                | 10 mg QD    | 10 mg QD    | 10 mg QD  | 10 mg QD  | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             |
| Bepotastine                   | 10 mg BID               | 10 mg BID               | 10 mg BID   | 10 mg BID   | 10 mg BID | 10 mg BID | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            |
| Levocetirizine                | 5 mg QD                 | 5 mg QD                 | 5 mg QD     | 5 mg QD     | 5 mg QD   | 5 mg QD   | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-7</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Olopatadine                   | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-8</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | 250 mg QD               | 250 mg QD               | 150 mg QD   | 100 mg QD   | 50 mg QD  | 50 mg QD  | 50 mg QD             | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Fexofenadine                  | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Levocetirizine                | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-9</b>                  |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Indometacin                   | 25 mg PRN               | 25 mg PRN               | 25 mg PRN   | 25 mg PRN   | 50 mg PRN | 50 mg PRN | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            | 50 mg PRN            |
| Prednisolone                  | 5 mg PRN                | 5 mg PRN                | 5 mg PRN    | 5 mg PRN    | 5 mg PRN  | 5 mg PRN  | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN |
| Diclofenac                    | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-10</b>                 |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                       | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP (N=11)</b>              |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>EP-1</b>                   |                         |                         |             |             |           |           |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Methotrexate                  | 5 mg twice a<br>week    | –                       | –           | –           | –         | –         | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |

|                               | Week      |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
|-------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
|                               | 1         | 2         | 4         | 8         | 12        | 16        | 20        | 24        | 28        | 32        | 36        | 40        | 44        | 48        | 52        |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| EP-2                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-3                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-4                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-5                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-6                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-7                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-8                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Ciclosporin                   | 50 mg BID | 50 mg BID | 50 mg BID | 50 mg BID | 50 mg BID | 50 mg BID | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-9                          |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| EP-10                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Epinalstine                   | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  |
| EP-11                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Dapsone                       | -         | -         | 25 mg BID | 25 mg BID | -         | -         | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID |
| Etretinate                    | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  |

## (b) Weeks 56–112

|                               | Week      |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
|-------------------------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
|                               | 56        | 60        | 64        | 68        | 72        | 76        | 80        | 84        | 88        | 92        | 96        | 100       | 104       | 108       | 112       |
| <b>GPP (N=10)</b>             |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| GPP-1                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| GPP-2                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| GPP-3                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Ciclosporin                   | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| GPP-4                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Etretinate                    | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| <b>BKZ 320 mg Q4W/Q8W/Q4W</b> |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| GPP-5                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| None                          | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         | -         |
| GPP-6                         |           |           |           |           |           |           |           |           |           |           |           |           |           |           |           |
| Prednisolone                  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  |
| Bepotastine                   | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID | 10 mg BID |


|                               | Week                 |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
|-------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                               | 56                   | 60                   | 64                   | 68                   | 72                   | 76                   | 80                   | 84                   | 88                   | 92                   | 96                   | 100                  | 104                  | 108                  | 112                  |
| Levocetirizine                | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-7</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Olopatadine                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | 5 md BID             | 5 md BID             |
| <b>GPP-8</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Fexofenadine                  | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | 60 mg BID            | –                    | –                    | –                    | –                    | –                    | –                    |
| Levocetirizine                | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              |
| <b>GPP-9</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Indometacin                   | 50 mg PRN            | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Prednisolone                  | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN |
| Diclofenac                    | –                    | 50 mg BID            | 50 mg BID            | 50 mg BID            | 50 mg BID            | 50 mg BID            | 50 mg BID            | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-10</b>                 |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP (N=11)</b>              |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>EP-1</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Methotrexate                  | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>EP-2</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-3</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-4</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-5</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-6</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-7</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-8</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-9</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-10</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Epinastine                    | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             | 20 mg QD             |
| <b>EP-11</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |                      |
| Dapsone                       | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            | 25 mg BID            |
| Etretinate                    | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             |

(c) Weeks 116–144

|                               | Week                 |                      |                      |                      |                      |                      |                      |                      |
|-------------------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|----------------------|
|                               | 116                  | 120                  | 124                  | 128                  | 132                  | 136                  | 140                  | 144                  |
| <b>GPP (N=10)</b>             |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-1</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-2</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-3</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-4</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Etretinate                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>BKZ 320 mg Q4W/Q8W/Q4W</b> |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-5</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-6</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Prednisolone                  | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             | 10 mg QD             |
| Bepotastine                   | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            | 10 mg BID            |
| Levocetirizine                | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>GPP-7</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Olopatadine                   | 5 md BID             | 5 md BID             | 5 md BID             | 5 md BID             | 5 md BID             | 5 md BID             | 5 md BID             | 5 md BID             |
| <b>GPP-8</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Ciclosporin                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Fexofenadine                  | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Levocetirizine                | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              | 5 mg QD              |
| <b>GPP-9</b>                  |                      |                      |                      |                      |                      |                      |                      |                      |
| Indometacin                   | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| Prednisolone                  | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN | 5 mg QD,<br>5 mg PRN |
| Diclofenac                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>GPP-10</b>                 |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP (N=11)</b>              |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>BKZ 320 mg Q4W/Q8W/Q8W</b> |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>EP-1</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |
| Methotrexate                  | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>BKZ 320 mg Q4W/Q4W/Q4W</b> |                      |                      |                      |                      |                      |                      |                      |                      |
| <b>EP-2</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-3</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-4</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |
| <b>EP-5</b>                   |                      |                      |                      |                      |                      |                      |                      |                      |
| None                          | –                    | –                    | –                    | –                    | –                    | –                    | –                    | –                    |

|             | Week      |           |           |           |           |           |           |           |
|-------------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|-----------|
|             | 116       | 120       | 124       | 128       | 132       | 136       | 140       | 144       |
| EP-6        |           |           |           |           |           |           |           |           |
| None        | –         | –         | –         | –         | –         | –         | –         | –         |
| EP-7        |           |           |           |           |           |           |           |           |
| None        | –         | –         | –         | –         | –         | –         | –         | –         |
| EP-8        |           |           |           |           |           |           |           |           |
| Ciclosporin | –         | –         | –         | –         | –         | –         | –         | –         |
| EP-9        |           |           |           |           |           |           |           |           |
| None        | –         | –         | –         | –         | –         | –         | –         | –         |
| EP-10       |           |           |           |           |           |           |           |           |
| Epinastine  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  | 20 mg QD  |
| EP-11       |           |           |           |           |           |           |           |           |
| Dapsone     | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID | 25 mg BID |
| Etretinate  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  | 10 mg QD  |


Safety set. Only systemic medications indicated for PSO, GPP, or EP are listed. Data are summarised according to the BKZ dosing the patients received. At Week 16, patients who achieved IGA 0/1 response were switched to BKZ 320 mg Q8W, while patients who did not achieve IGA 0/1 response remained on BKZ 320 mg Q4W. At Week 48, patients receiving BKZ 320 mg Q8W who achieved IGA 0/1 response remained on BKZ 320 mg Q8W, while those who did not achieve IGA 0/1 response were switched back to BKZ 320 mg Q4W. BID: twice a day; BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; PRN: when necessary; PSO: plaque psoriasis; Qam: every morning; Qn: every night; Q4W: every 4 weeks; Q8W: every 8 weeks; QD: every day.

**Figure S1. PASI 75 response to Week 144 in the (a) GPP and (b) EP populations.**


Full analysis set (observed case). PASI responses were evaluated only in patients with baseline PASI score >0 (GPP: N=10, EP: N=11). PASI 75 response defined as an improvement of  $\geq 75\%$  in PASI score from baseline. <sup>a</sup>At Week 16, patients who achieved IGA 0/1 response were switched to BKZ 320 mg Q8W, while patients who did not achieve IGA 0/1 response remained on BKZ 320 mg Q4W. <sup>b</sup>At Week 48, patients receiving BKZ 320 mg Q8W who achieved IGA 0/1 response remained on BKZ 320 mg Q8W, while those who did not achieve IGA 0/1 response were switched back to BKZ 320 mg Q4W. <sup>c</sup>BKZ was discontinued after Week 16 and before Week 144; or data were unavailable due to a missing visit. BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; PASI 75:  $\geq 75\%$  improvement from baseline in Psoriasis Area and Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks.



**Figure S2. PASI 100 response to Week 144 in the (a) GPP and (b) EP populations.**




Full analysis set (observed case). PASI responses were evaluated only in patients with baseline PASI score >0 (GPP: N=10, EP: N=11). PASI 100 response defined as an improvement of 100% in PASI score from baseline. <sup>a</sup>At Week 16, patients who achieved IGA 0/1 response were switched to BKZ 320 mg Q8W, while patients who did not achieve IGA 0/1 response remained on BKZ 320 mg Q4W. <sup>b</sup>At Week 48, patients receiving BKZ 320 mg Q8W who achieved IGA 0/1 response remained on BKZ 320 mg Q8W, while those who did not achieve IGA 0/1 response were switched back to BKZ 320 mg Q4W. <sup>c</sup>BKZ was discontinued after Week 16 and before Week 144; or data were unavailable due to a missing visit. BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; PASI 100: 100% improvement from baseline in Psoriasis Area and Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks.

**Figure S3. mNAPSI 75 response to Week 144 in the (a) GPP and (b) EP populations.**

Full analysis set (observed case). mNAPSI 75 response defined as an improvement of  $\geq 75\%$  in mNAPSI score from baseline. <sup>a</sup>mNAPSI responses were evaluated only in patients with baseline nail psoriasis, defined as mNAPSI score  $> 0$  (GPP: N=7, EP: N=10). <sup>b</sup>At Week 16, patients who achieved IGA 0/1 response were switched to BKZ 320 mg Q8W, while patients who did not achieve IGA 0/1 response remained on BKZ 320 mg Q4W. <sup>c</sup>At Week 48, patients receiving BKZ 320 mg Q8W who achieved IGA 0/1 response remained on BKZ 320 mg Q8W, while those who did not achieve IGA 0/1 response were switched back to BKZ 320 mg Q4W. <sup>d</sup>BKZ was discontinued after Week 16 and before Week 144. BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; mNAPSI 75:  $\geq 75\%$  improvement from baseline in modified Nail Psoriasis Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks.


**Figure S4. mNAPSI 90 response to Week 144 in the (a) GPP and (b) EP populations.**




Full analysis set (observed case). mNAPSI 90 response defined as an improvement of  $\geq 90\%$  in mNAPSI score from baseline. <sup>a</sup>mNAPSI responses were evaluated only in patients with baseline nail psoriasis, defined as mNAPSI score  $> 0$  (GPP: N=7, EP: N=10). <sup>b</sup>At Week 16, patients who achieved IGA 0/1 response were switched to BKZ 320 mg Q8W, while patients who did not achieve IGA 0/1 response remained on BKZ 320 mg Q4W. <sup>c</sup>At Week 48, patients receiving BKZ 320 mg Q8W who achieved IGA 0/1 response remained on BKZ 320 mg Q8W, while those who did not achieve IGA 0/1 response were switched back to BKZ 320 mg Q4W. <sup>d</sup>BKZ was discontinued after Week 16 and before Week 144. BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; IGA: Investigator's Global Assessment; mNAPSI 90:  $\geq 90\%$  improvement from baseline in modified Nail Psoriasis Severity Index; Q4W: every 4 weeks; Q8W: every 8 weeks.

**Figure S5. EQ-5D-3L VAS scores to Week 144 in the (a) GPP and (b) EP populations.**

**(a) GPP (N=10)<sup>a</sup>**




**(b) EP (N=11)<sup>d</sup>**




Full analysis set (observed case). The EQ-5D-3L VAS records the respondent's self-rated health status on a vertical 20 cm scale, graduated from 0 (worst imaginable health status) to 100 (best imaginable health status). <sup>a</sup>Data for patients with GPP presented as BKZ Total (N=10): BKZ 320 mg Q4W/Q8W/Q8W (n=4), BKZ 320 mg Q4W/Q8W/Q4W (n=2), and BKZ Q4W/Q4W/Q4W (n=4). <sup>b</sup>Data at Week 0 referred to the last valid measurement before the administration of BKZ. <sup>c</sup>Efficacy outcomes in patients who discontinued BKZ after Week 16 and before Week 144 were reported as missing. <sup>d</sup>Data for patients with EP presented as BKZ Total (N=11): BKZ 320 mg Q4W/Q8W/Q8W (n=1) and BKZ Q4W/Q4W/Q4W (n=10). BKZ: bimekizumab; EP: erythrodermic psoriasis; EQ-5D-3L: European Quality of Life-5 Dimensions-3 Levels; GPP: generalised pustular psoriasis; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation; VAS: visual analog scale.

**Figure S6. SF-36 PCS and MCS scores to Week 144 in the (a) GPP and (b) EP populations.**



**(a) GPP (N=10)<sup>a</sup>**



**(b) EP (N=11)<sup>d</sup>**





Full analysis set (observed case). The SF-36 is a 36-item instrument measuring the respondent's health-related QoL in terms of 8 domains and using a recall period of 4 weeks. Component scores (PCS and MCS) are derived from the 8 domain scores (excluding Health Transition), summarising the physical and mental dimensions of health status, respectively, and raw scores range from 0 to 100 (higher scores indicate better health-related QoL). Data presented for component scores (PCS and MCS) were standardised with a mean of 50 and standard deviation of 10 in the general United States population. <sup>a</sup>Data for patients with GPP presented as BKZ Total (N=10): BKZ 320 mg Q4W/Q8W/Q8W (n=4), BKZ 320 mg Q4W/Q8W/Q4W (n=2), and BKZ Q4W/Q4W/Q4W (n=4). <sup>b</sup>Data at Week 0 referred to the last valid measurement before the administration of BKZ. <sup>c</sup>Efficacy outcomes in patients who discontinued BKZ after Week 16 and before Week 144 were reported as missing. <sup>d</sup>Data for patients with EP presented as BKZ Total (N=11): BKZ 320 mg Q4W/Q8W/Q8W (n=1) and BKZ Q4W/Q4W/Q4W (n=10). BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; MCS: Mental Component Summary; PCS: Physical Component Summary; QoL: quality of life; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation; SF-36: Short Form 36-item Health Survey.

**Figure S7. WPAI-SHP score to Week 144 in the (a) GPP and (b) EP populations.****(a) GPP (N=10)<sup>a</sup>****(b) EP (N=11)<sup>e</sup>**

Full analysis set (observed case). The WPAI-SHP (version 2.0) [1, 2] is a patient-reported questionnaire that assesses the respondent's employment status, work absenteeism, work impairment while working (presenteeism), overall work, and daily activity impairment attributable to a specific health problem; 5 of 6 items assessed are regrouped into 4 dimensions, with their scores expressed as percentage (higher numbers indicate worse outcomes of greater impairment and less productivity). <sup>a</sup>Data for patients with GPP presented as BKZ Total (N=10): BKZ 320 mg Q4W/Q8W/Q8W (n=4), BKZ 320 mg Q4W/Q8W/Q4W (n=2), and BKZ Q4W/Q4W/Q4W (n=4). <sup>b</sup>Percent activity impairment was assessed in the GPP population with N=10 at Week 0 and Week 16, N=9 at Week 48, N=8 at Week 96, and N=7 at Week 144. <sup>c</sup>Data at Week 0 referred to the last valid measurement before the administration of BKZ. <sup>d</sup>Efficacy outcomes in patients who discontinued BKZ after Week 16 and before Week 144 were reported as missing. <sup>e</sup>Data for patients with EP presented as BKZ Total (N=11): BKZ 320 mg Q4W/Q8W/Q8W (n=1) and BKZ Q4W/Q4W/Q4W (n=10). <sup>f</sup>Percent activity impairment was assessed in the EP population with N=11 at Week 0 and Week 16. BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation; WPAI-SHP: Work Productivity and Activity Impairment Questionnaire-Specific Health Problem.

**Figure S8. TSQM-9 at Week 48 in the (a) GPP and (b) EP populations.**

■ Dissatisfied/difficult/inconvenient ■ Somewhat satisfied/easy/convenient ■ Satisfied/easy/convenient ■ Very satisfied/easy/convenient ■ Extremely satisfied/easy/convenient  
 ■ Somewhat confident/certain ■ Very confident/certain ■ Extremely confident/certain

**(a) GPP (N=10)<sup>a</sup>****(b) EP (N=11)<sup>c</sup>**

Full analysis set (observed case). The TSQM-9 [3, 4] is a 9-item measure of treatment satisfaction with medication, with 5–7 Likert response options per item and consists of 3 subscales: effectiveness (3 items), convenience (3 items), and a global satisfaction scale (3 items); scores range from 0 (worst) to 100 (best). 7 Likert scale: There were no patients with GPP or EP who provided responses of “Extremely dissatisfied/difficult/inconvenient” and “Very dissatisfied/difficult/inconvenient”, and no patients with EP who provided responses of “Dissatisfied/difficult/inconvenient” to any item. 5 Likert scale: There were no patients with GPP or EP who provided responses of “Not at all confident/certain” and “A little confident/certain” to any item. <sup>a</sup>Data for patients with GPP presented as BKZ Total (N=10): BKZ 320 mg Q4W/Q8W/Q8W (n=4), BKZ 320 mg Q4W/Q8W/Q4W (n=2), and BKZ Q4W/Q4W/Q4W (n=4). <sup>b</sup>Efficacy outcomes in patients who discontinued BKZ after Week 16 and before Week 144 were reported as missing. <sup>c</sup>Data for patients with EP presented as BKZ Total (N=11): BKZ 320 mg Q4W/Q8W/Q8W (n=1) and BKZ Q4W/Q4W/Q4W (n=10). BKZ: bimekizumab; EP: erythrodermic psoriasis; GPP: generalised pustular psoriasis; Q4W: every 4 weeks; Q8W: every 8 weeks; SD: standard deviation; TSQM-9: Treatment Satisfaction Questionnaire for Medication.

## REFERENCES

1. Reilly Associates. 'WPAI:SHP V2.0'. 2010. Available at: [http://www.reillyassociates.net/WPAI\\_SHP.html](http://www.reillyassociates.net/WPAI_SHP.html) (last accessed: 22 May 2025).
2. Reilly MC, Zbrozek AS, Dukes EM. 'The validity and reproducibility of a work productivity and activity impairment instrument'. *Pharmacoeconomics*. 1993;4(5):353–65.
3. IQVIA. 'Treatment Satisfaction Questionnaire for Medication (TSQM): Getting to the heart of patient treatment satisfaction'. 2007. Available at: <https://www.iqvia.com/solutions/research-and-development/consulting/patient-centered-endpoints/clinical-outcome-assessments-coa/tsqm> (last accessed: 22 May 2025).
4. Bharmal M, Payne K, Atkinson MJ, et al. 'Validation of an abbreviated Treatment Satisfaction Questionnaire for Medication (TSQM-9) among patients on antihypertensive medications'. *Health Qual Life Outcomes*. 2009;7:36.